Want to see ELV full AI Analyst Report?
ELV Stock Chart & Stats
$377.68
-$1.63(-0.43%)
At close: 4:00 PM EDT
$377.68
-$1.63(-0.43%)
Day’s Range― - ―
52-Week Range$274.84 - $436.24
Previous CloseN/A
Volume969.56K
Average Volume (3M)1.64M
Market Cap
$86.86B
Enterprise Value$115.45K
Total Cash (Recent Filing)$37.51B
Total Debt (Recent Filing)$31.04B
Price to Earnings (P/E)17.8
Beta0.45
Next Earnings
Oct 21, 2026EPS Estimate
4.7Next Dividend Ex-DateN/A
Dividend Yield1.71%
Share Statistics
EPS (TTM)22.50
Shares Outstanding216,869,300
10 Day Avg. Volume1,863,853
30 Day Avg. Volume1,644,011
Financial Highlights & Ratios
PEG Ratio-5.70
Price to Book (P/B)1.77
Price to Sales (P/S)0.39
P/FCF Ratio24.50
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$445.63Price Target Upside17.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering17
EPS Forecast (FY)27.14
Revenue Forecast (FY)$196.96B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthElevance is expanding its revenue base across health benefits and healthcare services. Sustained growth improves operating scale and supports investment in Carelon, technology and member capabilities, although execution remains important.
Carelon Scaling And Cost SavingsCarelon adds diversification beyond insurance premiums while its clinical programs can reduce medical costs. Scaling behavioral health, pharmacy and home-based care could strengthen retention, margins and long-term competitive differentiation.
Manageable Leverage And Positive Cash GenerationA sizable equity base and positive cash generation provide financial flexibility for claims obligations, technology investment and strategic growth. Manageable leverage also reduces balance-sheet risk as the company navigates medical-cost volatility.
Bears Say
Structural Margin CompressionLower margins indicate that medical utilization, reimbursement pressure or operating costs are absorbing more of each revenue dollar. Persistent compression would reduce earnings resilience and make results more dependent on pricing and execution.
Medicaid Losses And Market ExitsOngoing Medicaid losses expose Elevance to reimbursement and utilization risk while market exits can reduce membership and revenue scale. Although exits may improve portfolio quality, the transition can disrupt relationships and near-term profitability.
Volatile Cash ConversionPositive cash generation is not consistently translating from the company’s large revenue base, and the sharp decline in free-cash-flow growth signals volatility. Timing effects and claims-related movements may complicate funding and planning.
Elevance Health News
ELV FAQ
What was Elevance Health, Inc.’s price range in the past 12 months?
Elevance Health, Inc. lowest stock price was $274.84 and its highest was $436.24 in the past 12 months.
What is Elevance Health, Inc.’s market cap?
Elevance Health, Inc.’s market cap is $86.86B.
When is Elevance Health, Inc.’s upcoming earnings report date?
Elevance Health, Inc.’s upcoming earnings report date is Oct 21, 2026 which is in 59 days.
How were Elevance Health, Inc.’s earnings last quarter?
Elevance Health, Inc. released its earnings results on Jul 15, 2026. The company reported $7.45 earnings per share for the quarter, beating the consensus estimate of $6.211 by $1.239.
Is Elevance Health, Inc. overvalued?
According to Wall Street analysts Elevance Health, Inc.’s price is currently Undervalued.
Does Elevance Health, Inc. pay dividends?
Elevance Health, Inc. pays a Quarterly dividend of $1.72 which represents an annual dividend yield of 1.71%. See more information on Elevance Health, Inc. dividends here
What is Elevance Health, Inc.’s EPS estimate?
Elevance Health, Inc.’s EPS estimate is 4.7.
How many shares outstanding does Elevance Health, Inc. have?
Elevance Health, Inc. has 216,869,300 shares outstanding.
What happened to Elevance Health, Inc.’s price movement after its last earnings report?
Elevance Health, Inc. reported an EPS of $7.45 in its last earnings report, beating expectations of $6.211. Following the earnings report the stock price went down -8.543%.
Which hedge fund is a major shareholder of Elevance Health, Inc.?
Currently, no hedge funds are holding shares in ELV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elevance Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$445.63 (17.99% Upside)
$445.63 (17.99% Upside)
Blogger Sentiment
Bullish
ELV Sentiment 78%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 254.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $541.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.62%
12-Months-Change
Fundamentals
Return on Equity
1.71%
Trailing 12-Months
Asset Growth
3.69%
Trailing 12-Months
Company Description
Elevance Health, Inc.
Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.
ELV Company Deck
ELV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly constructive: management reported a quarter that beat expectations, raised 2026 EPS guidance, increased operating cash flow guidance, and highlighted scalable growth drivers (Medicare Advantage improvement, Carelon expansion, and technology-enabled cost management). Notable headwinds remain in Medicaid (projected -1.75% margin), concentrated utilization trends (behavioral health, specialty pharmacy, outpatient surgery, ED), planned market exits, and near-term investments that keep expense ratios elevated. Management emphasized prudence and one-time uses of the Q2 benefit while articulating confidence in returning to at least 12% adjusted EPS growth in 2027 based on diversified levers across the enterprise.View all ELV earnings summariesELV Stock 12 Month Forecast
Average Price Target
$445.63
▲(17.99% Upside)
Technical Analysis
Ownership Overview
0.17% Insiders
27.40% Mutual Funds
25.32% Other Institutional Investors
22.65% Public Companies and Individual Investors